Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABC-14 vs 3+7 vs AB-14 in Newly Diagnosed AML
NCT06451861Phase 2Recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Aug 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat in acute myeloid leukemia (AML), sponsored by Guangdong Provincial People's Hospital. Started Aug 2024; status: recruiting.
02
Drugs
tucidinostat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06451861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06451861.